FDA
-
-
-
-
-
-
-
Ideaya Biosciences (IDYA) PT Raised to $35 at Goldman Sachs
-
-
-
-
-
-
-
IDEAYA completes enrollment in phase 2/3 uveal melanoma trial
-
-
-
-
-
-
-
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
IDEAYA Biosciences submits IND for PRMT5 inhibitor IDE892
-
-
-
-
-
-
-
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
-
322,913 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

